809 related articles for article (PubMed ID: 17220241)
1. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
[TBL] [Abstract][Full Text] [Related]
3. Characterization of two cyclic metabolites of sitagliptin.
Liu DQ; Arison BH; Stearns RA; Kim D; Vincent SH
Drug Metab Dispos; 2007 Apr; 35(4):521-4. PubMed ID: 17220240
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
[TBL] [Abstract][Full Text] [Related]
5. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Bergman A; Ebel D; Liu F; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman G; Wagner J; Krishna R
Biopharm Drug Dispos; 2007 Sep; 28(6):315-22. PubMed ID: 17575559
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
Herman GA; Bergman A; Liu F; Stevens C; Wang AQ; Zeng W; Chen L; Snyder K; Hilliard D; Tanen M; Tanaka W; Meehan AG; Lasseter K; Dilzer S; Blum R; Wagner JA
J Clin Pharmacol; 2006 Aug; 46(8):876-86. PubMed ID: 16855072
[TBL] [Abstract][Full Text] [Related]
7. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Kim D; Wang L; Beconi M; Eiermann GJ; Fisher MH; He H; Hickey GJ; Kowalchick JE; Leiting B; Lyons K; Marsilio F; McCann ME; Patel RA; Petrov A; Scapin G; Patel SB; Roy RS; Wu JK; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
J Med Chem; 2005 Jan; 48(1):141-51. PubMed ID: 15634008
[TBL] [Abstract][Full Text] [Related]
8. Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.
Krishna R; Bergman A; Larson P; Cote J; Lasseter K; Dilzer S; Wang A; Zeng W; Chen L; Wagner J; Herman G
J Clin Pharmacol; 2007 Feb; 47(2):165-74. PubMed ID: 17244767
[TBL] [Abstract][Full Text] [Related]
9. Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
Bergman A; Mistry GC; Luo WL; Liu Q; Stone J; Wang A; Zeng W; Chen L; Dilzer S; Lasseter K; Herman GA; Wagner JA; Krishna R
Biopharm Drug Dispos; 2007 Sep; 28(6):307-13. PubMed ID: 17571284
[TBL] [Abstract][Full Text] [Related]
10. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.
Herman GA; Bergman A; Yi B; Kipnes M;
Curr Med Res Opin; 2006 Oct; 22(10):1939-47. PubMed ID: 17022853
[TBL] [Abstract][Full Text] [Related]
11. Metabolism and pharmacokinetics of a dipeptidyl peptidase IV inhibitor in rats, dogs, and monkeys with selective carbamoyl glucuronidation of the primary amine in dogs.
Beconi MG; Mao A; Liu DQ; Kochansky C; Pereira T; Raab C; Pearson P; Lee Chiu SH
Drug Metab Dispos; 2003 Oct; 31(10):1269-77. PubMed ID: 12975337
[TBL] [Abstract][Full Text] [Related]
12. Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects.
Mistry GC; Bergman AJ; Luo WL; Cilissen C; Haazen W; Davies MJ; Gottesdiener KM; Wagner JA; Herman GA
J Clin Pharmacol; 2007 Feb; 47(2):159-64. PubMed ID: 17244766
[TBL] [Abstract][Full Text] [Related]
13. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and excretion of RWJ-333369 [1,2-ethanediol, 1-(2-chlorophenyl)-, 2-carbamate, (S)-] in mice, rats, rabbits, and dogs.
Mamidi RN; Mannens G; Annaert P; Hendrickx J; Goris I; Bockx M; Janssen CG; Kao M; Kelley MF; Meuldermans W
Drug Metab Dispos; 2007 Apr; 35(4):566-75. PubMed ID: 17220243
[TBL] [Abstract][Full Text] [Related]
15. Orally active inhibitors of human leukocyte elastase. II. Disposition of L-694,458 in rats and rhesus monkeys.
Vincent SH; Painter SK; Luffer-Atlas D; Karanam BV; McGowan E; Cioffe C; Doss G; Chiu SH
Drug Metab Dispos; 1997 Aug; 25(8):932-9. PubMed ID: 9280401
[TBL] [Abstract][Full Text] [Related]
16. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.
Zhang D; He K; Raghavan N; Wang L; Mitroka J; Maxwell BD; Knabb RM; Frost C; Schuster A; Hao F; Gu Z; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2009 Aug; 37(8):1738-48. PubMed ID: 19420130
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
Prakash C; Cui D
Drug Metab Dispos; 1997 Dec; 25(12):1395-406. PubMed ID: 9394030
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys.
Tan EY; Hartmann G; Chen Q; Pereira A; Bradley S; Doss G; Zhang AS; Ho JZ; Braun MP; Dean DC; Tang W; Kumar S
Drug Metab Dispos; 2010 Mar; 38(3):459-73. PubMed ID: 20016052
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of the dipeptidyl peptidase 4 inhibitor saxagliptin in rats, dogs, and monkeys and clinical projections.
Fura A; Khanna A; Vyas V; Koplowitz B; Chang SY; Caporuscio C; Boulton DW; Christopher LJ; Chadwick KD; Hamann LG; Humphreys WG; Kirby M
Drug Metab Dispos; 2009 Jun; 37(6):1164-71. PubMed ID: 19251818
[TBL] [Abstract][Full Text] [Related]
20. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
Prakash C; Soliman V
Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
